SWA
AQST icon

SFMG Wealth Advisors’s Aquestive Therapeutics AQST Stock Holding History

SFMG Wealth Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.9K Sell
13,185
-581
-4% -$2.44K ﹤0.01% 337
2026
Q1 		$57.1K Hold
13,766
– – ﹤0.01% 320
2025
Q4 		$88.9K Buy
+13,766
New +$85.8K 0.01% 303

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

SFMG Wealth Advisors's AQST Position: Q2 2026 in Review

SFMG Wealth Advisors reduced its Aquestive Therapeutics (AQST) stake by 4.2% in Q2 2026, selling an estimated $2.44K and leaving 13,185 shares worth $54.9K. The position accounts for ﹤0.01% of the portfolio, ranked #337.

SFMG Wealth Advisors first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $88.9K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • SFMG Wealth Advisors held 13,185 shares of Aquestive Therapeutics worth $54.9K as of Q2 2026.
  • SFMG Wealth Advisors sold 581 Aquestive Therapeutics shares in Q2 2026, an estimated $2.44K.
  • Aquestive Therapeutics made up ﹤0.01% of SFMG Wealth Advisors's portfolio in Q2 2026, its #337 holding.
  • SFMG Wealth Advisors first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • SFMG Wealth Advisors's Aquestive Therapeutics position peaked at $88.9K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on SFMG Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.